JP2016539172A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539172A5
JP2016539172A5 JP2016536849A JP2016536849A JP2016539172A5 JP 2016539172 A5 JP2016539172 A5 JP 2016539172A5 JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016539172 A5 JP2016539172 A5 JP 2016539172A5
Authority
JP
Japan
Prior art keywords
ganglioside
carbohydrate
cancer
pharmaceutical composition
multimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/051165 external-priority patent/WO2015081438A1/en
Publication of JP2016539172A publication Critical patent/JP2016539172A/ja
Publication of JP2016539172A5 publication Critical patent/JP2016539172A5/ja
Pending legal-status Critical Current

Links

JP2016536849A 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物 Pending JP2016539172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
US61/912,684 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (2)

Publication Number Publication Date
JP2016539172A JP2016539172A (ja) 2016-12-15
JP2016539172A5 true JP2016539172A5 (cg-RX-API-DMAC7.html) 2017-03-09

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536849A Pending JP2016539172A (ja) 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物

Country Status (7)

Country Link
US (1) US10363305B2 (cg-RX-API-DMAC7.html)
EP (2) EP3957327A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016539172A (cg-RX-API-DMAC7.html)
CN (1) CN106414472A (cg-RX-API-DMAC7.html)
CA (1) CA2968995A1 (cg-RX-API-DMAC7.html)
ES (1) ES2904533T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015081438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786586B2 (en) * 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
EP4225365A4 (en) * 2020-10-05 2024-11-13 AOA Dx COMPOSITIONS AND METHODS FOR CANCER DIAGNOSTIC

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435025D1 (de) * 1993-01-22 2007-10-25 Sloan Kettering Inst Cancer Gangliosid-KLH-Konjugatimpfstoffe mit QS-21 zur Verzögerung des Wiederauftretens eines Melanoms
JP4262480B2 (ja) * 2000-11-29 2009-05-13 ブラッコ インターナショナル ビー.ヴイ. 結合能を有するシアリル・ルイスx類似物
AU2002354804A1 (en) * 2001-07-06 2003-01-21 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
JP4742339B2 (ja) * 2005-06-14 2011-08-10 独立行政法人産業技術総合研究所 シアル酸含有3糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
WO2007026669A1 (ja) * 2005-09-02 2007-03-08 Shizuoka Prefectural Universities Corporation ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Similar Documents

Publication Publication Date Title
JP2016506916A5 (cg-RX-API-DMAC7.html)
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
JP2016515561A5 (cg-RX-API-DMAC7.html)
JP2016506935A5 (cg-RX-API-DMAC7.html)
JP2017525730A5 (cg-RX-API-DMAC7.html)
JP2018502885A5 (cg-RX-API-DMAC7.html)
WO2017210617A3 (en) Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP2014176384A5 (cg-RX-API-DMAC7.html)
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201792407A3 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
JP2009536191A5 (cg-RX-API-DMAC7.html)
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2015512432A5 (cg-RX-API-DMAC7.html)
Bobrowicz et al. CD37 in B cell derived tumors—more than just a docking point for monoclonal antibodies
EA201590427A1 (ru) Нелинейные сахаридные конъюгаты
JP2015509075A5 (cg-RX-API-DMAC7.html)
RU2014139954A (ru) Активация прокаспазы-3 с помощью комбинированной терапии
CY1118254T1 (el) Αντισωματα toy βμρ-6
JP2016519107A5 (cg-RX-API-DMAC7.html)
JP2017506640A5 (cg-RX-API-DMAC7.html)
Westwood et al. Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice
JP2016539172A5 (cg-RX-API-DMAC7.html)